Baxter International
14
20M
11
0.15
5
0.21
2
- Areas of investment
Summary
In 1931 was created Baxter International, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Deerfield. The fund was located in North America if to be more exact in United States.
The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2015. Considering the real fund results, this Corporate Investor is 30 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Baxter International works on 4 percentage points less the average amount of lead investments.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Baxter International, startups are often financed by Versant Ventures, Seroba Life Sciences, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Sunstone Life Science Ventures, Roche Venture Fund, Novartis Venture Fund. In the next rounds fund is usually obtained by Takeda Ventures, Takeda Pharmaceutical, Sunstone Life Science Ventures.
Among the most successful fund investment fields, there are Medical, Therapeutics. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Gliknik, Opsona, Ocular Therapeutix. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 14
- Lead investments
- 5
- Exits
- 2
- Rounds per year
- 0.15
- Follow on index
- 0.21
- Investments by industry
- Biotechnology (10)
- Health Care (8)
- Medical (4)
- Therapeutics (4)
- Biopharma (3) Show 10 more
- Investments by region
-
- United States (10)
- Ireland (2)
- Canada (1)
- Austria (1)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 52M
- Group Appearance index
- 0.64
- Avg. company exit year
- 7
- Avg. multiplicator
- 2.80
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| NovaXS Biotech | 15 Mar 2022 | Health Care, Medical Device | Seed | 846K | United States, California, Berkeley |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.